Publications by authors named "W K Giermakowska"

Interleukin-6 (IL-6) is a pleotropic cytokine that signals through the membrane-bound IL-6 receptor (mIL-6R) to induce anti-inflammatory ("classic-signaling") responses. This cytokine also binds to the soluble IL-6R (sIL-6R) to promote inflammation ("trans-signaling"). mIL-6R expression is restricted to hepatocytes and immune cells.

View Article and Find Full Text PDF

Two processes are associated with progressive loss of renal function: 1) decreased aquaporin-2 (AQP2) expression and urinary concentrating capacity (Nephrogenic Diabetes Insipidus, NDI); and 2) changes in extracellular matrix (ECM) composition, e.g. increased collagen I (Col I) deposition, characteristic of tubule-interstitial fibrosis.

View Article and Find Full Text PDF

Inflammation is a prominent pathological feature in pulmonary arterial hypertension, as demonstrated by pulmonary vascular infiltration of inflammatory cells, including T and B lymphocytes. However, the contribution of the adaptive immune system is not well characterized in pulmonary hypertension caused by chronic hypoxia. CD4 T cells are required for initiating and maintaining inflammation, suggesting that these cells could play an important role in the pathogenesis of hypoxic pulmonary hypertension.

View Article and Find Full Text PDF

Sleep apnea is a risk factor for cardiovascular disease, and intermittent hypoxia (IH, 20 episodes/h of 5% O-5% CO for 7 h/day) to mimic sleep apnea increases blood pressure and impairs hydrogen sulfide (HS)-induced vasodilation in rats. The enzyme that produces HS, cystathionine γ-lyase (CSE), is decreased in rat mesenteric artery endothelial cells (EC) following in vivo IH exposure. In silico analysis identified putative nuclear factor of activated T cell (NFAT) binding sites in the CSE promoter.

View Article and Find Full Text PDF
Article Synopsis
  • Idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) can lead to serious lung issues like low oxygen levels and high blood pressure in the lungs, and they may involve the Nuclear Factor of Activated T-cells (NFAT) in their progression.
  • * Research indicates that Vasoactive Intestinal Peptide (VIP) may inhibit NFAT activity, and the study aimed to investigate how VIP and NFATc3 (a specific NFAT isoform) are linked to the severity of IPF and COPD.
  • * Results showed a negative correlation between NFATc3 levels and lung function in IPF patients, suggesting NFATc3 activation occurs early in the disease, and a positive correlation between VIP
View Article and Find Full Text PDF